Quick Answer
REGENXBIO Inc. reported Total Revenue of $170.44 million for fiscal year 2025.
REGENXBIO Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $170.44M +104.5% |
$83.33M -7.7% |
$90.24M -19.9% |
$112.72M -76.0% |
$470.35M +204.3% |
$154.57M +338.7% |
| Revenue (ASC 606) | $170.44M +104.5% |
$83.33M -7.7% |
$90.24M -19.9% |
$112.72M -76.0% |
$470.35M +204.3% |
$154.57M +338.7% |
| Net Income | -$193.88M +14.6% |
-$227.10M +13.8% |
-$263.49M +6.0% |
-$280.32M -319.3% |
$127.84M +214.9% |
-$111.25M -17.4% |
| Diluted EPS | -$3.76 +18.1% |
-$4.59 +23.8% |
-$6.02 +7.4% |
-$6.50 -323.4% |
$2.91 +197.7% |
-$2.98 -15.5% |
| Total Assets | $453.03M -2.8% |
$465.99M -18.8% |
$573.97M -31.1% |
$833.27M -25.2% |
$1.11B +57.3% |
$708.16M +42.2% |
| Cash and Equivalents | $34.47M -40.1% |
$57.53M +66.6% |
$34.52M -64.4% |
$96.95M -71.9% |
$345.21M +2.0% |
$338.43M +386.8% |
| Stockholders Equity | $102.73M -60.4% |
$259.65M -16.7% |
$311.74M -39.6% |
$516.20M -32.5% |
$764.30M +102.3% |
$377.75M -16.1% |
| R&D Expense | $228.30M +9.5% |
$208.52M -10.2% |
$232.27M -4.2% |
$242.45M +33.6% |
$181.44M +9.1% |
$166.29M +33.9% |
| Operating Income | -$161.20M +30.9% |
-$233.35M +13.0% |
-$268.13M -2.0% |
-$262.88M -264.3% |
$159.98M +234.2% |
-$119.23M +20.0% |
| Shares Outstanding | 50.89M +2.7% |
49.55M +12.5% |
44.05M +1.7% |
43.30M +1.1% |
42.83M +14.3% |
37.48M +1.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $29.73M | +22.9% | +39.2% |
| Revenue (ASC 606) | September 30, 2025 | $29.73M | +22.9% | +39.2% |
| Net Income | September 30, 2025 | -$61.94M | -3.9% | +12.6% |
| Diluted EPS | September 30, 2025 | -$1.20 | -2.6% | +13.0% |
| Total Assets | September 30, 2025 | $525.20M | +1.2% | -9.6% |
| Cash and Equivalents | September 30, 2025 | $58.80M | +3.9% | -26.1% |
| Stockholders Equity | September 30, 2025 | $161.45M | -46.4% | -24.4% |
| R&D Expense | September 30, 2025 | $56.10M | +3.1% | -5.7% |
| Operating Income | September 30, 2025 | -$52.41M | +15.6% | +17.2% |
| Shares Outstanding | September 30, 2025 | 50.62M | +2.2% | +0.5% |
- REGENXBIO Inc. reported Total Revenue of $170.44 million for fiscal year 2025.
- REGENXBIO Inc. showed an increase of +104.5% in Total Revenue compared to the prior fiscal year.
- REGENXBIO Inc. reported Revenue (ASC 606) of $170.44 million for fiscal year 2025.
- REGENXBIO Inc. showed an increase of +104.5% in Revenue (ASC 606) compared to the prior fiscal year.
- REGENXBIO Inc. reported Net Income of -$193.88 million for fiscal year 2025.
- REGENXBIO Inc. showed an increase of +14.6% in Net Income compared to the prior fiscal year.
- REGENXBIO Inc. reported Diluted EPS of $3.76 per share (loss) for fiscal year 2025.
- REGENXBIO Inc. showed an increase of +18.1% in Diluted EPS compared to the prior fiscal year.
- REGENXBIO Inc. reported Total Assets of $453.03 million for fiscal year 2025.
- REGENXBIO Inc. showed a decrease of -2.8% in Total Assets compared to the prior fiscal year.
- REGENXBIO Inc. reported Cash and Equivalents of $34.47 million for fiscal year 2025.
- REGENXBIO Inc. showed a decrease of -40.1% in Cash and Equivalents compared to the prior fiscal year.
- REGENXBIO Inc. reported Stockholders Equity of $102.73 million for fiscal year 2025.
- REGENXBIO Inc. showed a decrease of -60.4% in Stockholders Equity compared to the prior fiscal year.
- REGENXBIO Inc. reported R&D Expense of $228.30 million for fiscal year 2025.
- REGENXBIO Inc. showed an increase of +9.5% in R&D Expense compared to the prior fiscal year.
- REGENXBIO Inc. reported Operating Income of -$161.20 million for fiscal year 2025.
- REGENXBIO Inc. showed an increase of +30.9% in Operating Income compared to the prior fiscal year.
- REGENXBIO Inc. reported Shares Outstanding of 50.89 million shares for fiscal year 2025.
- REGENXBIO Inc. showed an increase of +2.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: